Possible Augmentation Of NB-UVB Induced Pigmentation In NSV By Carboxy.
NB-UVB
Evaluation Of Carboxytherapy As An Adjuvant To Narrowband-Ultraviolet B Phototherapy For The Treatment Of Stable Non-Segmental Vitiligo: A Clinical And Biochemical Study .
1 other identifier
interventional
59
1 country
1
Brief Summary
Patients with stable vitiligo with 2 or more symmetric patches, 2 on acral sites and/or 2 on non acral sites will be recruited and assessed for eligibility for inclusion to receive NB-UVB on the whole body, and carboxytherapy on one randomized side.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Sep 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 22, 2025
CompletedFirst Submitted
Initial submission to the registry
April 25, 2026
CompletedFirst Posted
Study publicly available on registry
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedMay 1, 2026
April 1, 2026
1.3 years
April 25, 2026
April 25, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
Vitiligo Extent Score for a Target Area (VESTA)
Assessment of the treatment response in a target area Range 0-100%
6 months- 1 year
Estimation of human E-Cadherin using ELISA
6 months -1 year
Estimation of malondialdehyde by spectrophotometer
6 months-1 year
Secondary Outcomes (1)
Patients' global satisfaction
6 months -1 year
Study Arms (2)
NB-UVB
PLACEBO COMPARATORNB-UVB combined with carboxy
ACTIVE COMPARATORInterventions
Narrow-Band Ultraviolet B phototherapy full cabin combined with Intradermal injection of carbon dioxide gas
Eligibility Criteria
You may qualify if:
- Subjects with stable non-segmental vitiligo (≥2 symmetrical patches of diameter less than 2 cm on acral or ≥ 2 symmetrical patches on non-acral sites). Subjects were stable for twelve or more months.
You may not qualify if:
- Subjects with unstable vitiligo.
- Subjects with segmental vitiligo.
- Pregnant females.
- Severe anemia (Hb \<7 gm/dl).
- Cardiac/hepatic/renal/respiratory failure.
- Superficial thrombophlebitis.
- Subjects with history of skin malignancy or precancerous conditions like Xeroderma pigmentosum.
- Subjects with other autoimmune disorders.
- Systemic drugs for vitiligo in the last 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Medicine, Cairo University
Cairo, El Manial, 11956, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 25, 2026
First Posted
May 1, 2026
Study Start
September 15, 2024
Primary Completion
December 22, 2025
Study Completion (Estimated)
June 1, 2026
Last Updated
May 1, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL